The Cost-Effectiveness of Ustekinumab Compared to Infliximab And Adalimumab in Adult Patients with Moderate-Severe Crohn's Disease (Tnf Naïve Population)
May 1, 2018, 00:00
10.1016/j.jval.2018.04.569
https://www.valueinhealthjournal.com/article/S1098-3015(18)30869-6/fulltext
Title :
The Cost-Effectiveness of Ustekinumab Compared to Infliximab And Adalimumab in Adult Patients with Moderate-Severe Crohn's Disease (Tnf Naïve Population)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)30869-6&doi=10.1016/j.jval.2018.04.569
First page :
Section Title :
Open access? :
No
Section Order :
1363